Ken Griffin Taysha Gene Therapies, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 15,900 shares of TSHA stock, worth $31,958. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,900
Previous 65,200
75.61%
Holding current value
$31,958
Previous $187,000
81.28%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding TSHA
# of Institutions
108Shares Held
136MCall Options Held
65.4KPut Options Held
41.7K-
Rtw Investments, LP New York, NY18.8MShares$37.8 Million0.7% of portfolio
-
Avoro Capital Advisors LLC New York, NY18.7MShares$37.5 Million0.57% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$23.6 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$21.9 Million0.37% of portfolio
-
Vr Adviser, LLC New York, NY9MShares$18.1 Million2.21% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $97.2M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...